These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28948002)

  • 21. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
    Richter B; Derntl M; Marx M; Lercher P; Gössinger HD
    Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Voluntary oral feeding of rats not requiring a very high fat diet is a clinically relevant animal model of non-alcoholic fatty liver disease (NAFLD).
    Tipoe GL; Ho CT; Liong EC; Leung TM; Lau TY; Fung ML; Nanji AA
    Histol Histopathol; 2009 Sep; 24(9):1161-9. PubMed ID: 19609863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females.
    Patel D; Mohanty P; Di Biase L; Wang Y; Shaheen MH; Sanchez JE; Horton RP; Gallinghouse GJ; Zagrodzky JD; Bailey SM; Burkhardt JD; Lewis WR; Diaz A; Beheiry S; Hongo R; Al-Ahmad A; Wang P; Schweikert R; Natale A
    Europace; 2010 Mar; 12(3):322-30. PubMed ID: 20064822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress.
    Qiang X; Xu L; Zhang M; Zhang P; Wang Y; Wang Y; Zhao Z; Chen H; Liu X; Zhang Y
    Biochem Biophys Res Commun; 2016 Apr; 472(4):603-9. PubMed ID: 26970305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood urea nitrogen is elevated in patients with non-alcoholic fatty liver disease.
    Liu X; Zhang H; Liang J
    Hepatogastroenterology; 2013; 60(122):343-5. PubMed ID: 23858556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of aldosterone and angiotensin II in insulin resistance: an update.
    Lastra-Lastra G; Sowers JR; Restrepo-Erazo K; Manrique-Acevedo C; Lastra-González G
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):1-6. PubMed ID: 19138313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications.
    Lau YF; Yiu KH; Siu CW; Tse HF
    J Hum Hypertens; 2012 Oct; 26(10):563-9. PubMed ID: 22129612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.
    Savelieva I; Kakouros N; Kourliouros A; Camm AJ
    Europace; 2011 Mar; 13(3):308-28. PubMed ID: 21345926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is atrial fibrillation an inflammatory disorder?
    Boos CJ; Anderson RA; Lip GY
    Eur Heart J; 2006 Jan; 27(2):136-49. PubMed ID: 16278230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease.
    Byrne CD; Targher G
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1155-61. PubMed ID: 24743428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-alcoholic fatty liver disease; a part of the metabolic syndrome in the renal transplant recipient and possible cause of an allograft dysfunction.
    Mikolasevic I; Racki S; Lukenda V; Pavletic-Persic M; Milic S; Orlic L
    Med Hypotheses; 2014 Jan; 82(1):36-9. PubMed ID: 24280560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?
    Emdin M; Fatini C; Mirizzi G; Poletti R; Borrelli C; Prontera C; Latini R; Passino C; Clerico A; Vergaro G
    Clin Chim Acta; 2015 Mar; 443():85-93. PubMed ID: 25445411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation.
    Korantzopoulos P; Kolettis TM; Galaris D; Goudevenos JA
    Int J Cardiol; 2007 Feb; 115(2):135-43. PubMed ID: 16764958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Role of ACE-inhibitors in preventing atrial fibrillation relapses in normotensive patients].
    Belluzzi F; Sernesi L; Centola M; Perlini S
    Recenti Prog Med; 2009 Nov; 100(11):508-11. PubMed ID: 20066882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of aldosterone and mineralocorticoid receptor antagonism on cardiac ion channels in the view of upstream therapy of atrial fibrillation.
    Laszlo R; Bentz K; Schreieck J
    Gen Physiol Biophys; 2011 Mar; 30(1):11-9. PubMed ID: 21460407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis.
    Arvaniti VA; Thomopoulos KC; Tsamandas A; Makri M; Psyrogiannis A; Vafiadis G; Assimakopoulos SF; Labropoulou-Karatza C
    Acta Gastroenterol Belg; 2008; 71(4):355-60. PubMed ID: 19317274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-alcoholic fatty liver and the gut microbiota.
    Bashiardes S; Shapiro H; Rozin S; Shibolet O; Elinav E
    Mol Metab; 2016 Sep; 5(9):782-94. PubMed ID: 27617201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease.
    Li L; Hai J; Li Z; Zhang Y; Peng H; Li K; Weng X
    Food Chem Toxicol; 2014 Jan; 63():166-73. PubMed ID: 23978414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.